Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
ARTV Stock Chart & Stats
$4.47
$0.32(3.02%)
At close: 4:00 PM EST
$4.47
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $7.36
Previous CloseN/A
Volume23.16K
Average Volume (3M)234.46K
Market Cap
$119.04M
Enterprise Value$88.04M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 30, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding24,544,905
10 Day Avg. Volume164,741
30 Day Avg. Volume234,463
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.32
Price to Sales (P/S)978.41
P/FCF Ratio-4.41
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.67Price Target Upside317.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Community Adoption And AccessThe simplicity of the AlloNK plus anti-CD20 antibody regimen and its benign safety profile enabled outpatient administration in community rheumatology sites, which could broaden patient access and facilitate faster commercial uptake compared with therapies requiring specialized centers.
Mechanism-driven EfficacyConsistent and complete B-cell depletion followed by reconstitution of naive B cells supports an immune reset mechanism that could translate into durable clinical benefit for autoimmune indications.
Safety ProfileClinical data indicate AlloNK combined with an anti-CD20 antibody produced no cytokine release syndrome, no neurotoxicity, no graft-versus-host disease, and no high-grade AlloNK-related adverse events in treated patients, suggesting a markedly cleaner safety profile than many other cell therapies.
Bears Say
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $7.36 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $119.04M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 59 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.868 by -$0.012.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,544,905 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.868. Following the earnings report the stock price went up 10.864%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (317.67% Upside)
$18.67 (317.67% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 283.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.60%
12-Months-Change
Fundamentals
Return on Equity
-47.96%
Trailing 12-Months
Asset Growth
-34.01%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$18.67
▲(317.67% Upside)
Technical Analysis
Adicet Bio
―
ABVC BioPharma
―
Jasper Therapeutics
―
Pliant Therapeutics
―
Repare Therapeutics
―
Ownership Overview
11.37% Insiders
1.98% Mutual Funds
61.60% Other Institutional Investors
24.09% Public Companies and Individual Investors
Options Prices
Currently, No data available
---